256640-45-6|J-113397|1-[(3R,4R)-1-(cyclooctylmethyl)-3-(hydroxymethyl)piperidin-4-yl]-3-ethylbenzimidazol-2-one|-范德生物科技公司

J-113397

NMR下载 COA and HPLC MSDS下载
names：
1-[(3R,4R)-1-(cyclooctylmethyl)-3-(hydroxymethyl)piperidin-4-yl]-3-ethylbenzimidazol-2-one
CAS号：
256640-45-6
MDL Number：
MF(分子式)： C24H37N3O2 MW(分子量)： 399.58
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	J-113397
英文别名	J-113397; J 113397; J113397.
CAS号	256640-45-6
SMILES	O=C1N(CC)C2=CC=CC=C2N1[C@H]3[C@H](CO)CN(CC4CCCCCCC4)CC3
Inchi	InChI=1S/C24H37N3O2/c1-2-26-22-12-8-9-13-23(22)27(24(26)29)21-14-15-25(17-20(21)18-28)16-19-10-6-4-3-5-7-11-19/h8-9,12-13,19-21,28H,2-7,10-11,14-18H2,1H3/t20-,21+/m0/s1
InchiKey	MBGVUMXBUGIIBQ-LEWJYISDSA-N
分子式 Formula	C24H37N3O2
分子量 Molecular Weight	399.58
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	J-113397(CAS:256640-45-6):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	J-113397 is a potent and selective NOP receptor antagonist (IC50 values are 2.3, 1400, 2200 and > 10000 nM for NOP, κ, μ and δ-opioid receptors respectively). J-113397 inhibits nociceptin/orphanin FQ-induced hyperalgesia in the mouse tail-flick test.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Scoto GM, Aricò G, Ronsisvalle S, Parenti C. Effects of intraplantar nocistatin and (±)-J 113397 injections on nociceptive behavior in a rat model of inflammation. Pharmacol Biochem Behav. 2012 Jan;100(3):639-44. doi: 10.1016/j.pbb.2011.11.007. PubMed PMID: 22120202.

[2]Visanji NP, de Bie RM, Johnston TH, McCreary AC, Brotchie JM, Fox SH. The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov Disord. 2008 Oct 15;23(13):1922-5. doi: 10.1002/mds.22086. PubMed PMID: 18759357.

[3] Smith ED, Ariane Vinson N, Zhong D, Berrang BD, Catanzaro JL, Thomas JB, Navarro HA, Gilmour BP, Deschamps J, Carroll FI. A new synthesis of the ORL-1 antagonist 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidinyl]-3-ethyl-1,3-dihydro- 2H-benzimidazol-2-one (J-113397) and activity in a calcium mobilization assay. Bioorg Med Chem. 2008 Jan 15;16(2):822-9. PubMed PMID: 17976996; PubMed Central PMCID: PMC2323199.

[4] Marti M, Trapella C, Viaro R, Morari M. The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway. J Neurosci. 2007 Feb 7;27(6):1297-307. PubMed PMID: 17287504.

[5] Trapella C, Guerrini R, Piccagli L, Calo' G, Carra' G, Spagnolo B, Rubini S, Fanton G, Hebbes C, McDonald J, Lambert DG, Regoli D, Salvadori S. Identification of an achiral analogue of J-113397 as potent nociceptin/orphanin FQ receptor antagonist. Bioorg Med Chem. 2006 Feb 1;14(3):692-704. PubMed PMID: 16202610.

6: Chiou LC, Fan SH. CompB (J-113397), selectively and competitively antagonizes nociceptin activation of inwardly rectifying K(+) channels in rat periaqueductal gray slices. Neuropharmacology. 2002 Jun;42(7):987-92. PubMed PMID: 12069909.7: De Risi C, Piero Pollini G, Trapella C, Peretto I, Ronzoni S, Giardina GA. A new synthetic approach to 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-be nzimidazol-2-one(J-113397), the first non-peptide ORL-1 receptor antagonist.. Bioorg Med Chem. 2001 Jul;9(7):1871-7. PubMed PMID: 11425589.8: Ichikawa D, Ozaki S, Azuma T, Nambu H, Kawamoto H, Iwasawa Y, Takeshima H, Ohta H. In vitro inhibitory effects of J-113397 on nociceptin/orphanin FQ-stimulated. Neuroreport. 2001 Jun 13;12(8):1757-61. PubMed PMID: 11409754.9: Ozaki S, Kawamoto H, Itoh Y, Miyaji M, Azuma T, Ichikawa D, Nambu H, Iguchi T, Iwasawa Y, Ohta H. In vitro and in vivo pharmacological characterization of J-113397, a potent and selective non-peptidyl ORL1 receptor antagonist. Eur J Pharmacol. 2000 Aug 18;402(1-2):45-53. PubMed PMID: 10940356.10: Bigoni R, Calo' G, Rizzi A, Guerrini R, De Risi C, Hashimoto Y, Hashiba E, Lambert DG, Regoli D. In vitro characterization of J-113397, a non-peptide nociceptin/orphanin FQ receptor antagonist. Naunyn Schmiedebergs Arch Pharmacol. 2000 May;361(5):565-8. PubMed PMID: 10832612.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开